Juno Therapeutics, Inc. (NASDAQ:JUNO) Director Richard Klausner sold 12,000 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $42.66, for a total value of $511,920.00. Following the completion of the sale, the director now owns 783,536 shares of the company’s stock, valued at $33,425,645.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Richard Klausner also recently made the following trade(s):

  • On Monday, August 7th, Richard Klausner sold 12,000 shares of Juno Therapeutics stock. The stock was sold at an average price of $30.34, for a total value of $364,080.00.
  • On Friday, July 7th, Richard Klausner sold 24,000 shares of Juno Therapeutics stock. The stock was sold at an average price of $29.39, for a total value of $705,360.00.

Shares of Juno Therapeutics, Inc. (JUNO) traded down 1.78% on Friday, reaching $41.85. The company had a trading volume of 1,850,028 shares. Juno Therapeutics, Inc. has a 52 week low of $17.52 and a 52 week high of $44.60. The company’s market capitalization is $4.39 billion. The company has a 50 day moving average of $31.69 and a 200-day moving average of $26.26.

Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.24. The company had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.64) earnings per share. Analysts predict that Juno Therapeutics, Inc. will post ($3.12) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/08/insider-selling-juno-therapeutics-inc-juno-director-sells-12000-shares-of-stock.html.

Several equities research analysts have weighed in on JUNO shares. Vetr cut Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $27.60 target price for the company. in a report on Tuesday, June 20th. BidaskClub upgraded Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 20th. Zacks Investment Research upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a report on Tuesday, July 11th. Morgan Stanley upped their target price on Juno Therapeutics from $26.00 to $27.00 and gave the stock an “equal weight” rating in a report on Monday, August 7th. Finally, FBR & Co reiterated a “hold” rating on shares of Juno Therapeutics in a report on Thursday, May 18th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $34.88.

A number of large investors have recently added to or reduced their stakes in JUNO. The Manufacturers Life Insurance Company boosted its holdings in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the period. Pacad Investment Ltd. purchased a new position in Juno Therapeutics in the second quarter valued at $105,000. QS Investors LLC purchased a new position in Juno Therapeutics in the second quarter valued at $135,000. Great West Life Assurance Co. Can boosted its holdings in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 3,800 shares during the period. Finally, Nisa Investment Advisors LLC purchased a new position in Juno Therapeutics in the first quarter valued at $200,000. Hedge funds and other institutional investors own 70.76% of the company’s stock.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.